S&P 500   5,248.07 (+-0.01%)
DOW   39,783.23 (+0.06%)
QQQ   444.85 (+0.00%)
AAPL   172.32 (-0.57%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   180.36 (+0.29%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.05 (-0.30%)
BABA   72.02 (+0.60%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.75 (-13.59%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
S&P 500   5,248.07 (+-0.01%)
DOW   39,783.23 (+0.06%)
QQQ   444.85 (+0.00%)
AAPL   172.32 (-0.57%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   180.36 (+0.29%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.05 (-0.30%)
BABA   72.02 (+0.60%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.75 (-13.59%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
S&P 500   5,248.07 (+-0.01%)
DOW   39,783.23 (+0.06%)
QQQ   444.85 (+0.00%)
AAPL   172.32 (-0.57%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   180.36 (+0.29%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.05 (-0.30%)
BABA   72.02 (+0.60%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.75 (-13.59%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
S&P 500   5,248.07 (+-0.01%)
DOW   39,783.23 (+0.06%)
QQQ   444.85 (+0.00%)
AAPL   172.32 (-0.57%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   180.36 (+0.29%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.05 (-0.30%)
BABA   72.02 (+0.60%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.75 (-13.59%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
NASDAQ:CODX

Co-Diagnostics (CODX) Stock Price, News & Analysis

$1.14
+0.03 (+2.70%)
(As of 09:02 AM ET)
Today's Range
$1.14
$1.14
50-Day Range
$1.06
$1.30
52-Week Range
$0.98
$1.89
Volume
1,785 shs
Average Volume
64,562 shs
Market Capitalization
$35.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50

Co-Diagnostics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
125.2% Upside
$2.50 Price Target
Short Interest
Bearish
1.22% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.10
Upright™ Environmental Score
News Sentiment
0.30mentions of Co-Diagnostics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.37 out of 5 stars

Medical Sector

322nd out of 939 stocks

Surgical & Medical Instruments Industry

43rd out of 99 stocks

CODX stock logo

About Co-Diagnostics Stock (NASDAQ:CODX)

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

CODX Stock Price History

CODX Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Q4 2023 Co-Diagnostics Inc Earnings Call
CODX Mar 2024 1.500 call
Co-Diagnostics: Q4 Earnings Insights
Earnings Preview: Co-Diagnostics
Here's what to expect from Co-Diagnostics's earnings
Co-Diagnostics Inc Registered Shs CODX
CODX Co-Diagnostics, Inc.
See More Headlines
Receive CODX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Co-Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2021
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:CODX
Fax
N/A
Employees
155
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.50
High Stock Price Target
$2.50
Low Stock Price Target
$2.50
Potential Upside/Downside
+125.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-35,330,000.00
Net Margins
-518.69%
Pretax Margin
-559.47%

Debt

Sales & Book Value

Annual Sales
$6.81 million
Book Value
$2.81 per share

Miscellaneous

Free Float
30,510,000
Market Cap
$34.70 million
Optionable
Optionable
Beta
-0.67
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Dwight H. Egan (Age 71)
    Chairman & CEO
    Comp: $415.75k
  • Mr. Brian L. Brown CPA (Age 48)
    CFO & Company Secretary
    Comp: $338.92k
  • Mr. Richard David Abbott (Age 52)
    President
  • Dr. Brent C. Satterfield Ph.D. (Age 47)
    Co-Founder & Member of Scientific Advisory Board
    Comp: $237.5k
  • Mr. Dan Bohrer CPA
    Vice President of Finance & Accounting
  • Dr. Mark Poritz Ph.D.
    Chief Scientific Officer
  • Mr. Andrew Benson
    Head of Investor Relations
  • Dr. Mayuranki Almaula
    Senior Vice President of Overseas Operations & Strategic Alliances
  • Mr. Cameron Gundry
    Head of Commercialization LATAM/EUR
  • Ms. Ivory Chang
    Chief Regulatory Affairs Officer

CODX Stock Analysis - Frequently Asked Questions

Should I buy or sell Co-Diagnostics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CODX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CODX, but not buy additional shares or sell existing shares.
View CODX analyst ratings
or view top-rated stocks.

What is Co-Diagnostics' stock price target for 2024?

1 Wall Street analysts have issued 1-year price targets for Co-Diagnostics' shares. Their CODX share price targets range from $2.50 to $2.50. On average, they expect the company's share price to reach $2.50 in the next year. This suggests a possible upside of 125.2% from the stock's current price.
View analysts price targets for CODX
or view top-rated stocks among Wall Street analysts.

How have CODX shares performed in 2024?

Co-Diagnostics' stock was trading at $1.33 at the start of the year. Since then, CODX stock has decreased by 16.5% and is now trading at $1.11.
View the best growth stocks for 2024 here
.

Are investors shorting Co-Diagnostics?

Co-Diagnostics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 381,500 shares, an increase of 11.8% from the February 29th total of 341,300 shares. Based on an average daily volume of 90,100 shares, the days-to-cover ratio is presently 4.2 days.
View Co-Diagnostics' Short Interest
.

When is Co-Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CODX earnings forecast
.

How were Co-Diagnostics' earnings last quarter?

Co-Diagnostics, Inc. (NASDAQ:CODX) released its quarterly earnings data on Thursday, November, 11th. The company reported $0.38 EPS for the quarter, topping the consensus estimate of $0.21 by $0.17. The firm had revenue of $30.10 million for the quarter, compared to the consensus estimate of $24 million. Co-Diagnostics had a negative net margin of 518.69% and a negative trailing twelve-month return on equity of 35.37%. During the same period in the previous year, the business earned $0.53 earnings per share.

What other stocks do shareholders of Co-Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Moderna (MRNA), Vaxart (VXRT), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), iBio (IBIO), Advanced Micro Devices (AMD), Pfizer (PFE) and Johnson & Johnson (JNJ).

When did Co-Diagnostics IPO?

Co-Diagnostics (CODX) raised $9 million in an initial public offering (IPO) on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO.

Who are Co-Diagnostics' major shareholders?

Co-Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Kestra Advisory Services LLC (0.45%), Physician Wealth Advisors Inc. (0.10%), SMI Advisory Services LLC (0.06%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brian Lee Brown, Eugene Durenard and Reed L Benson.
View institutional ownership trends
.

How do I buy shares of Co-Diagnostics?

Shares of CODX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CODX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners